Application of OSMI-1 in preparation of medicine for treating airway mucus hypersecretion disease
By using OSMI-1 as an O-GlcNAc transferase inhibitor, the intracellular O-GlcNAcylation is solved, and the existing drugs for treating high secretion of airway mucus are limited and side effects are achieved to reduce airway mucus secretion and improve respiration Functional effect.
Patent Information
- Application Number
- CN202411017755.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing drug treatments for airway mucus hypersecretion diseases such as mucus dissolving agents and anticholinergic drugs have limited effects and side effects, and physical therapy equipment is expensive and not suitable for all patients, especially children and the elderly.
Using OSMI-1 as an O-GlcNAc transferase inhibitor, reduces the secretion of airway mucus by inhibiting the level of O-GlcNAcylation in cells. It is designed as a drug preparation for injection or intranasal administration, and is used to treat asthma and chronic obstructive lungs. Diseases and bronchodilation.
OSMI-1 effectively reduces the production and mucus secretion of MUC5AC and MUC5B mucin, reduces disease symptoms, improves respiratory system functions, and has better safety and durability than traditional methods.
Smart Images

Figure CN118903129A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to application of OSMI-1 in preparing medicines for treating diseases with airway mucus hypersecretion. Background Art
[0002] Respiratory diseases are a major health problem worldwide. Diseases characterized by high secretion of airway mucus include asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, etc., which have a serious impact on the quality of life and health of patients. Airway mucus is composed of mucus proteins and water secreted by epithelial cells. Under physiological conditions, these mucus proteins combine with water to form a layer of mucus covering the surface of the respiratory tract, which can effectively capture and remove harmful substances in the respiratory tract, such as bacteria, viruses, dust and other particulate matter, thereby protecting the respiratory tract from the external environment. However, under pathological conditions, the physiological function of airway mucin may be affected, leading to abnormal secretion and clearance of airway mucus. This will lead to excessive secretion of mucus, making the mucus too viscous, blocking the airway and aggravating the symptoms of the disease. In addition, excessive secretion of mucus will also increase airway resistance, leading to difficulty breathing and susceptibility to infection. Among them, MUC5AC and MUC5B are the main components of mucin, which are mainly present in respiratory epithelial cells, and mucin (MUC5AC, MUC5B) is often highly expressed in airway mucus hypersecretion. Therefore, with the advancement of molecular biology and drug development technology, finding new treatment strategies to alleviate the symptoms of respiratory diseases and improve the quality of life of patients has become a research focus.
[0003] At present, the existing technical solutions for the treatment of airway mucus hypersecretion mainly cover two categories: drug therapy and physical therapy. Drug therapy includes mucolytics and anticholinergic drugs. However, the disadvantage of mucolytics is that they have limited effects on some patients and may cause gastrointestinal discomfort and allergic reactions. The disadvantage of anticholinergic drugs is that long-term use may cause side effects such as dry mouth and blurred vision. In addition, there are some Chinese herbal ingredients that show some practicality in the treatment of this disease, such as Qingjin Yiqi Fang (patent number: CN116531472B), Shabufa Toxin Jing (patent number: CN108721306B), etc. In the current treatment strategies for airway mucus hypersecretion, some drugs, such as enzyme cutting agents (such as DNA enzymes, lysozymes), mucus regulators (such as acetylgalactonate) and chloride channel activators, have been used in clinical treatment or are in the research stage. However, their therapeutic effects and safety still need further research and evaluation. Finally, physical therapy includes: breathing training and vibration expectoration and postural drainage (patent number: CN307672277S). The main disadvantage is that the equipment required is expensive and requires regular maintenance, which may not be applicable to children and the elderly. In addition, this requires patient cooperation and lasts for a long time, which is not applicable to some patients with serious conditions. Summary of the invention
[0004] In order to solve the above technical problems, an embodiment of the present invention provides the use of OSMI-1 in preparing a drug for treating airway mucus hypersecretion diseases.
[0005] To achieve the above object, the embodiments of the present invention adopt the following technical solutions:
[0006] In one aspect, the present invention provides the use of OSMI-1 in the preparation of a drug for treating airway mucus hypersecretion diseases.
[0007] In some embodiments, the structural formula of OSMI-1 is:
[0008]
[0009] In some embodiments, the airway mucus hypersecretion disease comprises at least one of asthma, chronic obstructive pulmonary disease and bronchiectasis.
[0010] In some embodiments, the drug is administered by injection or intranasally.
[0011] In some embodiments, the drug comprises a pharmaceutical preparation prepared by taking an effective amount of OSMI-1 as an active ingredient and adding a pharmaceutically acceptable carrier and / or excipient.
[0012] The OSMI-1 compound provided by the present invention is intended to inhibit OGT, thereby reducing the intracellular O-GlcNAcylation level, and then play a role in treating respiratory diseases characterized by high secretion of airway mucus. 1. Description of therapeutic effect: The OSMI-1 compound is designed to reduce the level of O-GlcNAc modification in cells, which plays an important role in regulating various protein functions and cellular processes. By inhibiting O-GlcNAc transferase, OSMI-1 is expected to affect the metabolic and signal transduction pathways in lung tissue, thereby improving airway mucus secretion. This pharmacological action is expected to play a positive role in alleviating disease symptoms and improving respiratory system function. Although further experimental research and analysis are required to directly quantify the specific effects of intracellular O-GlcNAc modification levels, according to structural characteristics and theoretical speculation, OSMI-1 reduces the tendency of high secretion of airway mucus by reducing the level of O-GlcNAcylation, thereby helping to alleviate symptoms associated with such diseases. This effect can be reflected in the reduction of mucin production (MUC5AC, MUC5B) and mucus secretion in cell culture models and animal experiments. 2. Structural characteristics and theoretical explanation: The design goal of the OSMI-1 compound is to be a specific inhibitor of O-GlcNAc transferase. Previous studies have shown that OSMI-1 (10-100 μM) reduces global O-GlcNAcylation in a dose-dependent manner after 24 hours of action on CHO (a laboratory-cultured cell line derived from Chinese hamster ovary cells) cells. This is because its structure can affect the catalytic activity or substrate binding of the enzyme, thereby interfering with the process of intracellular O-GlcNAcylation. This intervention will lead to the regulation of signaling pathways related to airway mucus hypersecretion, reduce mucus production and cellular inflammatory response, and is expected to improve the pathological process of related respiratory diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1a The results of Western Blot detection of O-GlcNAC, MUC5AC and MUC5B after PCN (5 μg / mL) was applied at different time points (0 h, 6 h, 12 h, 24 h) in cell experiments;
[0014] Figure 1b Statistical results of Western Blot detection of O-GlcNAC;
[0015] Figure 1c Statistical results of Western Blot detection of MUC5AC;
[0016] Figure 1d Statistical results of Western Blot detection of MUC5B;
[0017] Figure 2a The results of Western Blot detection of O-GlcNAC, MUC5AC, and MUC5B in cell experiments after different concentrations of PCN (0 μg / mL, 2.5 μg / mL, 5 μg / mL, and 10 μg / mL) acted on cells for 24 hours;
[0018] Figure 2b Statistical results of Western Blot detection of O-GlcNAC;
[0019] Figure 2c Statistical results of Western Blot detection of MUC5AC;
[0020] Figure 2d Statistical results of Western Blot detection of MUC5B;
[0021] Figure 3a The results of Western Blot detection of O-GlcNAC, MUC5AC and MUC5B in cell experiments after PCN (5 μg / mL) and OSMI-1 (10 μM) acted on cells for 24 hours;
[0022] Figure 3b Statistical results of Western Blot detection of O-GlcNAC;
[0023] Figure 3c Statistical results of Western Blot detection of MUC5AC;
[0024] Figure 3d Statistical results of Western Blot detection of MUC5B;
[0025] Figure 4 The statistical results are as follows: cells were treated with different concentrations of PCN (0μg / mL, 2.5μg / mL, 5μg / mL, 10μg / mL), and OSMI-1 (10μM) was treated for 1 hour and then different concentrations of PCN (0μg / mL, 2.5μg / mL, 5μg / mL, 10μg / mL) were added. After 24 hours of action, the cell survival rate was detected using CCK-8;
[0026] Figure 5a The results of detecting reactive oxygen species in cell experiments after PCN (5μg / mL) and OSMI-1 (10μM) acted on cells for 24 hours;
[0027] Figure 5b is the statistical result of active oxygen detection;
[0028] Figure 6aThe results of detecting mitochondrial reactive oxygen species in cell experiments after PCN (5μg / mL) and OSMI-1 (10μM) acted on cells for 24 hours;
[0029] Figure 6b This is the statistical result of mitochondrial reactive oxygen species detection;
[0030] Figure 7 This is the HE staining result of lung tissue in animal experiments;
[0031] Figure 8 This is the result of AB-PAS staining of lung tissue in animal experiments;
[0032] Figure 9a The results of immunohistochemical detection of O-GlcNAC in lung tissue in animal experiments;
[0033] Figure 9b Statistical results of immunohistochemical detection of O-GlcNAC;
[0034] Fig.10a The results of immunohistochemical detection of MUC5AC in lung tissue in animal experiments;
[0035] Fig.10b Statistical results of immunohistochemical detection of MUC5AC;
[0036] Fig.11a The results of immunohistochemical detection of MUC5B in lung tissue in animal experiments;
[0037] Fig.11b Statistical results of immunohistochemical detection of MUC5B. DETAILED DESCRIPTION
[0038] The following will be combined with the accompanying drawings to clearly and completely describe the technical solutions in some embodiments of the present disclosure. Obviously, the described embodiments are only part of the embodiments of the present disclosure, rather than all the embodiments. Based on the embodiments provided by the present disclosure, all other embodiments obtained by ordinary technicians in this field belong to the scope of protection of the present disclosure.
[0039] At present, the existing technical solutions for the treatment of airway mucus hypersecretion mainly cover two categories: drug therapy and physical therapy. Drug therapy includes mucolytics and anticholinergic drugs. However, the disadvantage of mucolytics is that they have limited effects on some patients and may cause gastrointestinal discomfort and allergic reactions. The disadvantage of anticholinergic drugs is that long-term use may cause side effects such as dry mouth and blurred vision. The embodiment of the present invention proposes the use of OSMI-1 in the preparation of drugs for the treatment of airway mucus hypersecretion diseases. OSMI-1 is a cell-permeable O-GlcNAc transferase (OGT) inhibitor, IC 50The value is 2.7 μM. OSMI-1 can inhibit protein O-linked N-acetylglucosamine (O-GlcNAcylation) in mammalian cell lines without qualitatively changing the N- or O-linked glycans on the cell surface. In addition, the structural formula of OSMI-1 is:
[0040]
[0041] The airway mucus hypersecretion disease may include at least one of asthma, chronic obstructive pulmonary disease and bronchiectasis.
[0042] The drug includes a pharmaceutical preparation prepared with an effective amount of OSMI-1 as an active ingredient and a pharmaceutically acceptable carrier and / or excipient. The effective amount refers to the amount of drug, compound, or pharmaceutical composition necessary to obtain any one or more beneficial or desired therapeutic results. Beneficial or desired results include: clinical improvement (such as reducing morbidity, reducing mortality, improving one or more symptoms), reducing severity, delaying the onset of symptoms (including symptoms or their complications, intermediate pathological phenotypes presented during the development of the symptoms, biochemical, histological, and / or behavioral symptoms). The preparation can be an injection, spray, aerosol, nasal drop, oral preparation, or a dosage form suitable for mucosal administration. In addition, the route of administration to the subject includes, but is not limited to, intramuscular, intravenous, subcutaneous, intradermal, oral, intranasal, respiratory, transmucosal, sublingual, and parenteral.
[0043] The experimental reagents used in the experiments of the present invention are shown in Table 1 below. In addition, the components of the AB-PAS staining kit are shown in Table 2 below, and the components of the general two-step kit (mouse / rabbit enhanced polymer detection system) are shown in Table 3 below.
[0044] Table 1
[0045]
[0046] Table 2
[0047]
[0048]
[0049] Table 3
[0050] name Specification save Reagent 1: Endogenous peroxidase blocker 3mL 2-8℃, protected from light Reagent 2: Reaction Enhancement Solution 3mL 2-8℃, protected from light Reagent 3: Enhanced enzyme-labeled goat anti-mouse / rabbit IgG polymer 3mL 2-8℃, protected from light
[0051] 1. Cell experiment:
[0052] 1. Experimental Materials and Methods:
[0053] ① Cell selection and treatment: Currently, human lung adenocarcinoma cell line (NCI-H292) is mostly used to study airway mucus secretion. NCI-H292 is preserved in RPMI-1640 medium, and 10% fetal bovine serum and 1% penicillin-streptomycin solution are added to the medium. It is cultured in a cell culture incubator at 5% CO2 and 37°C. When the cells grow well and the growth density is maintained at 80% to 90%, the required drug stimulation treatment is added. Pyocyanin (PCN, pyocyanin) concentration (5μg / mL) is used to treat cells, and the cells are collected after the action time is 0h, 6h, 12h, and 24h. Pyocyanin (PCN, pyocyanin) is treated with different concentrations (0μg / mL, 2.5μg / mL, 5μg / mL, 10μg / mL), and the cells are collected after the action time is 24h. The control group (CON) was not treated, the PCN group (PCN) was added with PCN (5μg / mL), the OSMI-1 group (OS) was added with OSMI-1 (10μM), and the OSMI-1+PCN (O+P) group was treated with OSMI-1 (10μM) for 1 hour in advance and then PCN (5μg / mL) was added. The cells were collected after 24 hours of action.
[0054] ②Western blot experiment: O-GlcNAC protein was detected using 10% SDS-polyacrylamide gel, and MUC5AC and MUC5B protein were detected using one-dimensional sodium dodecyl sulfate-agarose / polyacrylamide gel (1D SDS-AgPAGE) gradient gel. The 1D SDS-AgPAGE gradient gel used by the inventor is a modified 1% agarose / 3-6% polyacrylamide gradient gel, and the preparation steps are as follows: two solutions (①3% SDS-polypropylene, 1% agarose, 10% glycerol, ②6% SDS-polypropylene, 1% agarose, 10% glycerol), ① and ② are heated at 50°C respectively to fully dissolve the agarose, and then 1.5μL of N,N,N',N'-tetramethylethylenediamine and 0.5μL of ammonium persulfate are added to each solution according to each 10mL, and finally the two solutions are mixed in a volume ratio of ①:②=2:3, and cast into a modified 1% agarose / 3-6% polyacrylamide gradient gel at 50°C. The prepared cell sample is subjected to corresponding gel electrophoresis according to different proteins to be detected.
[0055] Experimental steps:
[0056] 1) Sample preparation and lysis: Collect cell samples, add lysis buffer (containing protease inhibitors), and lyse the cells to release proteins.
[0057] 2) Protein separation: The lysed samples were subjected to gel electrophoresis, and 10% SDS-polyacrylamide gel or 1% agarose / 3-6% polyacrylamide gradient gel was selected according to the different proteins to be detected.
[0058] 3) Electrophoretic transfer: Transfer the proteins in the gel to a polyvinylidene fluoride (PVDF) membrane so that the protein bands migrate to the membrane.
[0059] 4) Blocking: Use protein blocking agent (5% skim milk) to block non-specific binding sites and reduce the non-specific binding of subsequent antibodies.
[0060] 5) Primary antibody incubation: Incubate the membrane with a specific primary antibody, which can specifically bind to the target protein.
[0061] 6) Washing: Wash the membrane with washing buffer to remove unbound primary antibody.
[0062] 7) Secondary antibody incubation: Incubate the membrane with enzyme-labeled secondary antibody, which can bind to the primary antibody.
[0063] 8) Washing: Wash the membrane again with washing buffer to remove unbound secondary antibody.
[0064] 9) Signal detection: Detect the target protein using a chemiluminescent agent, generating a band signal to show its presence and relative amount.
[0065] ③CCK-8: Oriscience Cell Counting Kit-8 (CCK-8 kit) is a rapid and highly sensitive kit based on WST-8 that is widely used in cell proliferation and cytotoxicity detection. The principle is that the highly water-soluble tetrazolium salt WST-8 is reduced by the dehydrogenase produced by the cell in the presence of an electron carrier to produce a water-soluble formazan dye, and the amount of formazan produced is proportional to the number of living cells. The number of living cells can be indirectly reflected by measuring the absorbance at 450nm.
[0066] Experimental steps:
[0067] 1) Inoculate 100 μL of cell suspension into each well of a 96-well plate.
[0068] 2) The cells were treated according to the experimental design (PCN at different concentrations (0 μg / mL, 2.5 μg / mL, 5 μg / mL, 10 μg / mL) and OSMI-1 (10 μM) were treated for 1 h and then PCN at different concentrations (0 μg / mL, 2.5 μg / mL, 5 μg / mL, 10 μg / mL) for 24 h.
[0069] 3) After cell treatment, add CCK-8 reagent at 10 μL / well.
[0070] 4) Incubate in a cell culture incubator for 1 hour.
[0071] 5) Measure the absorbance at 450 nm.
[0072] 6) Calculate the cell survival rate (%) = [(AB) / (CB)] × 100 (A = absorbance of the experimental well, B = absorbance of the blank well, C = absorbance of the control well).
[0073] ④ Reactive Oxygen Species Assay Kit (also known as ROS Assay Kit) is a kit for reactive oxygen species detection using the fluorescent probe DCFH-DA. DCFH-DA itself has no fluorescence and can freely pass through the cell membrane. After entering the cell, it can be hydrolyzed by the esterase in the cell to produce DCFH. However, DCFH cannot penetrate the cell membrane, making it easy for the probe to be loaded into the cell. The reactive oxygen species in the cell can oxidize the non-fluorescent DCFH to produce fluorescent DCF. By detecting the fluorescence of DCF, the level of reactive oxygen species in the cell can be known.
[0074] Experimental steps:
[0075] 1) Dilute DCFH-DA at 1:1000 with serum-free culture medium to a final concentration of 10 μmol / L.
[0076] 2) Remove the cell culture medium and add an appropriate volume of diluted DCFH-DA.
[0077] 3) Incubate in a 37°C cell culture incubator for 20 minutes.
[0078] 4) Wash the cells three times with serum-free cell culture medium to fully remove DCFH-DA that has not entered the cells.
[0079] 5) Observe using a fluorescence microscope.
[0080] ⑤ Mitochondrial reactive oxygen species detection: MitoSOX Red is a live cell fluorescent probe that specifically targets mitochondria and has cell membrane permeability. MitoSOX Red will be oxidized by superoxide after entering the mitochondria. The oxidized MitoSOX Red then binds to the nucleic acids in the mitochondria / nucleus to produce strong red fluorescence. MitoSOX Red can be used as a fluorescent indicator to specifically detect superoxide.
[0081] Experimental steps:
[0082] 1) Dilute 50 μg MitoSOX Red with 13 μL anhydrous DMSO to prepare a 5 mM stock solution, and then dilute the stock solution with PBS to prepare a 5 μM MitoSOX Red working solution.
[0083] 2) Culture the adherent cells on sterile coverslips.
[0084] 3) Remove the coverslip from the culture medium and remove the excess culture medium by aspirating.
[0085] 4) Add 100 μL of dye working solution, shake gently to completely cover the cells, and incubate for 25 minutes.
[0086] 5) Aspirate the dye working solution and wash with culture medium 2-3 times, 5 minutes each time.
[0087] 6) Observe using a fluorescence microscope.
[0088] 2. Experimental results:
[0089] ① Figure 1a-1d As shown in the figure, in the different time gradients of PCN action, the expression of O-GlcNAC, MUC5AC, and MUC5B showed an upward trend over time. The protein expression of O-GlcNAC, MUC5AC, and MUC5B was detected by Western Blot method. The protein results after PCN (5μg / mL) acted at different time points (0h, 6h, 12h, 24h). [*P<0.05, **P<0.01, ***P<0.001, ****P<0.0001].
[0090] ② Figure 2a-2d As shown in the figure, in cells treated with different concentrations of PCN, the expression of O-GlcNAC, MUC5AC, and MUC5B increased with the increase of concentration. The protein expression of O-GlcNAC, MUC5AC, and MUC5B was detected by Western Blot method. The protein results after different concentrations of PCN (0μg / mL, 2.5μg / mL, 5μg / mL, 10μg / mL) acted on cells for 24 hours. [*P<0.05,**
[0091] P<0.01,***P<0.001].
[0092] ③ Figure 3a-3d As shown and combined Figure 1a-1d and Figure 2a-2dThe results showed that when PCN caused the increase of mucin (MUC5AC and MUC5B) protein levels, O-GlcNAC levels also increased, and it was time-concentration gradient dependent. OSMI-1 inhibited OGT, reduced intracellular O-GlcNAC levels, and alleviated the PCN-induced mucin (MUC5AC and MUC5B) expression. The protein expression of O-GlcNAC, MUC5AC, and MUC5B was detected by Western Blot. The protein results after PCN (5μg / mL) and OSMI-1 (10μM) acted on cells for 24h. [*P<0.05, **P<0.01, ***P<0.001].
[0093] ④ Figure 4 As shown in the cells pretreated with different concentrations of PCN by OSMI-1, OSMI-1 can enhance the decrease in cell survival rate caused by PCN. The survival rate of cells was detected by CCK-8. Cells were treated with different concentrations of PCN (0μg / mL, 2.5μg / mL, 5μg / mL, 10μg / mL), and OSMI-1 (10μM) was treated for 1h and then different concentrations of PCN (0μg / mL, 2.5μg / mL, 5μg / mL, 10μg / mL) were added for 24h. [*P<0.05, **P<0.01, ***P<0.001].
[0094] Combination Figure 3a-3d The results showed that OSMI-1 could improve the expression of mucin by increasing the survival rate of cells.
[0095] ⑤ Figure 5a-Figure 5b Previous studies have shown that PCN-induced cell damage, which leads to high mucin expression, is often accompanied by cellular redox imbalance, mainly manifested as an increase in ROS. The results of the detection of cellular reactive oxygen species show that OSMI-1 can improve the damage caused by PCN to cells by reducing the production of ROS [*P<0.05, ****P<0.0001].
[0096] ⑥ Figure 6a-6b As shown in the figure, mitochondria, as the most important organelle in regulating the cellular redox system, play an important role in regulating the production of ROS. By detecting the production of mitochondrial ROS, it can be seen that PCN can cause an increase in mitochondrial ROS, resulting in mitochondrial dysfunction. However, OSMI-1 can reduce the production of mitochondrial ROS, thereby alleviating the functional imbalance of mitochondria under the action of PCN, [****P<0.0001].
[0097] From the results of cell experiments ( Figure 1a-1d as well as Figure 6a-6b) It can be seen that PCN can reduce cell survival rate and cause cellular redox imbalance (increased production of ROS and mitochondrial ROS), while OSMI-1 can increase cell survival rate, regulate redox imbalance, and reduce the expression of mucin (MUC5AC, MUC5B) by inhibiting OGT and reducing O-GlcNAC.
[0098] 2. Animal Experiments:
[0099] 1. Experimental Materials and Methods:
[0100] ① Animal experiment selection and treatment: C57BL / 6 mice (male, about 20 g each, 6-8 weeks old) were raised in an environment of 18-25℃ and 50-70% relative humidity, with a 12-hour light / dark cycle. After the mice were adaptively fed for 7 days. We randomly divided the mice into 3 groups, 6 in each group, namely the control group, PAO1 group, and OSMI-1+PAO1 group. The control group (CON) was intranasally dripped with PBS, the PAO1 group mice were intranasally dripped with PAO1 (1*10^6CFU), and the OSMI-1+PAO1 group (O+PA) was intraperitoneally injected with OSMI-1 (10 mg / Kg) 1 h before the intranasal drip of PAO1 (1*10^6CFU). The mice were kept in an upright position for about 1 min during the intranasal drip of PAO1 to ensure that the bacterial liquid entered the airway and was distributed as evenly as possible in both lungs. The above treatment was performed on the 1st, 3rd, 5th and 7th days of the experiment. The diet, hair, body weight, respiration and other changes of mice in each group were observed every day. On the 8th day, bilateral lung tissues of mice were collected and fixed in 4% paraformaldehyde for 48 hours, and then dehydrated, fixed and paraffin embedded. Finally, the paraffin-embedded tissues were prepared into pathological sections for HE staining, AB-PAS staining and immunohistochemical staining to detect the expression levels of O-GlcNAC, MUC5AC and MUC5B. Animal experiment grouping modeling:
[0101] CON: PBS, 25 μL, mouse nasal drops;
[0102] PAO1: PAO1, 25 μL mouse nasal drops, to establish a mouse airway mucus hypersecretion model;
[0103] OSMI-1+PAO1 (O+PA): PAO1, 25 μL of OSMI-1 was intraperitoneally injected into mice intranasally at 10 mg / kg.
[0104] ②Hematoxylin and eosin (HE) staining: Hematoxylin is a basic natural dye that appears blue in alkaline solution, so it can dye the cell nucleus blue. Eosin is a chemically synthesized acidic dye that can color the cytoplasm red under certain conditions.
[0105] Experimental steps:
[0106] 1) Dewaxing of sections: xylene twice, 10 min each time → anhydrous ethanol twice, 5 min each time → 95% anhydrous ethanol, 5 min → 90% anhydrous ethanol, 5 min → 80% anhydrous ethanol, 5 min → rinse with distilled water, 3 min.
[0107] 2) Staining with hematoxylin solution, 5 min → rinse with distilled water, 5 s → differentiate with hydrochloric acid ethanol, 3 s → rinse with tap water, 30 s → return to blue, 40 s → dehydrate with 80% anhydrous ethanol, 60 s → stain with eosin staining solution (alcohol soluble) for 30 s.
[0108] 3) Dehydration, transparency, and sealing: 80% anhydrous ethanol, 10s → 90% anhydrous ethanol, 20s → 95% anhydrous ethanol twice, 2min each time → anhydrous ethanol twice, 2min each time → xylene transparency 3 times, 3min each time → neutral gum sealing. Staining results: cell nuclei are blue, cytoplasm, muscle fibers, collagen fibers, thyroid colloid, etc. are red in different shades, and keratin, red blood cells, etc. are bright orange-red.
[0109] ③Alcian blue-periodic acid-Schiff (AB-PAS) staining: Alcian blue and PAS techniques can be used together to identify neutral mucin and acidic mucin in the same tissue section. This technique is also commonly used as a means of extensive detection of mucin. If the staining is negative, it can be clearly determined that the substance is not mucin.
[0110] Experimental steps:
[0111] 1) Dewax the paraffin sections into water (same as the dewax into water step in HE staining).
[0112] 2) Reagent (A) Stain with Alcian Blue solution for 10-20 minutes and then wash with distilled water three times, each time for 1-2 minutes.
[0113] 3) Oxidation was carried out in reagent (B) periodic acid solution for 5 minutes.
[0114] 4) Finally, stain with reagent (C) Schiff Reagent for 10-20 minutes. Pour off the Schiff Reagent and rinse with running water for 10 minutes.
[0115] 5) Stain the nuclei with hematoxylin staining solution for 1-2 minutes, then differentiate with acidic differentiation solution for 2-5 seconds and wash with water.
[0116] 6) Scott bluing solution turns blue and wash with water for 3 minutes.
[0117] 7) Dehydration, transparency, and sealing (same steps as HE staining). Staining results: glycogen, neutral mucin, various glycoproteins - purple-red; acidic mucin (sulfur mucin and sialomucin) - blue; proteoglycan and hyaluronic acid - blue. Cells or tissues containing neutral mucin and acidic mucin can be stained with varying degrees of blue-purple to purple.
[0118] ④Immunohistochemical staining
[0119] Experimental steps:
[0120] 1) Dewaxing and hydration: Paraffin sections were placed in fresh xylene, soaked for 3 times, 10 min each time → placed in anhydrous ethanol, soaked for 3 times, 3 min each time → placed in 95% anhydrous ethanol, soaked for 2 times, 3 min each time → placed in 75% anhydrous ethanol, soaked for 2 times, 3 min each time → rinsed with distilled water for 1 min, and placed in PBS buffer.
[0121] 2) Antigen retrieval.
[0122] 3) Blocking endogenous peroxidase: Add an appropriate amount of endogenous peroxidase blocker and incubate at room temperature for 10 minutes; rinse with PBS buffer 3 times, 3 minutes each time.
[0123] 4) Add primary antibody: Add 100 μL or appropriate amount of primary antibody according to the size of the tissue, incubate at 37°C for 60 min; rinse with PBS buffer 3 times, 3 min each time.
[0124] 5) Add reaction enhancement solution: add 100 μL or an appropriate amount of reaction enhancement solution, incubate at 37°C for 20 min; rinse with PBS buffer 3 times, 3 min each time.
[0125] 6) Add enhanced enzyme-labeled goat anti-mouse / rabbit IgG polymer: add 100 μL or an appropriate amount of enhanced enzyme-labeled goat anti-mouse / rabbit IgG polymer, incubate at 37°C for 20 minutes; rinse with PBS buffer 3 times, 3 minutes each time.
[0126] 7) DAB color development: Add an appropriate amount of freshly prepared DAB color development solution and incubate at room temperature for 5 minutes.
[0127] 8) Re-staining: Rinse with tap water, incubate with hematoxylin staining solution for 20 seconds; differentiate with hydrochloric acid and ethanol, rinse and turn blue.
[0128] 9) Dehydrate, transparentize, and seal with neutral resin (same steps as HE staining).
[0129] Result determination: If the target antigen in the target tissue cells is observed to be brown-yellow (DAB color development), it is a positive result, otherwise it is negative.
[0130] 2. Experimental results:
[0131] ① Figure 7 The HE staining results showed that OSMI-1 could improve PAO1-induced damages such as congestion, neutrophil infiltration, alveolar hemorrhage and cell proliferation in the lung tissue of mice.
[0132] ② Figure 8 The AB-PAS staining results shown in the figure showed that more blue substances were visible in the bronchi of the PAO1 group, indicating that PAO1 successfully established an airway mucus hypersecretion model and that OSMI-1 could reduce the secretion of various mucins in the airways.
[0133] ③ Figure 9a-9b as well as Figure 10a-Figure 10b as well as Figure 11a-Figure 11b The results show that OSMI-1 can reduce the high expression of O-GlcNAC and mucin (MUC5AC, MUC5B) in the airway, which is consistent with the previous cell experiment results. Figure 9b Medium [*P<0.05], Fig.10b Medium [**P<0.01, ***P<0.001], Fig.11b Medium [**P<0.01].
[0134] From the results of animal experiments ( Figure 7 , Figure 8 , Figure 9a-9b as well as Figure 10a-Figure 10b as well as Figure 11a-Figure 11b ) It can be seen that in an animal model of airway mucus hypersecretion, OSMI-1 can alleviate pathological changes in lung tissue, reduce airway mucus secretion and mucin expression.
[0135] Experimental data analysis and statistics: The experimental data of cell experiments and animal experiments were quantitatively analyzed using GraphPadPrism 9 analysis software. In the statistical results, * means P<0.05, ** means P<0.01, *** means P<0.001, **** means P<0.0001, and ns means no statistical difference.
[0136] In the description of this specification, specific features, structures, materials or characteristics may be combined in an appropriate manner in any one or more embodiments or examples.
[0137] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims
1. Application of OSMI-1 in the preparation of drugs for the treatment of airway mucus hypersecretion diseases.
2. The use according to claim 1, characterized in that: The structural formula of OSMI-1 is:
3. The use according to claim 1, characterized in that: The airway mucus hypersecretion disease includes at least one of asthma, chronic obstructive pulmonary disease and bronchiectasis.
4. The use according to claim 1, characterized in that: The drug is administered by injection or intranasally.
5. The use according to claim 1, characterized in that: The medicine comprises a pharmaceutical preparation prepared by taking an effective amount of OSMI-1 as an active ingredient and adding a pharmaceutically acceptable carrier and / or auxiliary material.
Citation Information
Patent Citations
Application of Bufotoxin in Asthma Prevention / Treatment Drugs
CN108721306B
Application of a Chinese medicine composition in preparing a drug for improving airway remodeling
CN116531472B
O-glcnac transferase (OGT) inhibitors and uses thereof
US20170166558A1
